Phio Pharmaceuticals Corp... (PHIO)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.79 |
Market Cap | 8.65M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -9.75 |
PE Ratio (ttm) | -0.19 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.84 |
Volume | 243,833 |
Avg. Volume (20D) | 6,556,770 |
Open | 1.83 |
Previous Close | 1.79 |
Day's Range | 1.79 - 1.88 |
52-Week Range | 1.53 - 10.35 |
Beta | undefined |
About PHIO
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic pr...
Analyst Forecast
According to 1 analyst ratings, the average rating for PHIO stock is "Buy." The 12-month stock price forecast is $36, which is an increase of 1888.95% from the latest price.